Mark Andersen

Mark Andersen

Director of Finance/CFO at FIBROBIOLOGICS, INC.

53 year
Health Technology
Commercial Services
Consumer Services

Profile

Mark Andersen is currently the Chief Financial Officer at FibroBiologics, Inc. He previously worked as the Investments Director-Pension Plan at Eli Lilly & Co. from 2004 to 2015, Vice President-Finance & Controller at MiMedx, Inc. from 2015 to 2016, Head-Controller at Lilly USA LLC, Auditor at Deloitte Development LLC from 1998 to 1999, and Auditor at KPMG US LLP from 1996 to 1998.
He also served as the Chief Financial Officer & VP-Administration at Indiana Biosciences Research Institute from 2016 to 2022.
Andersen received his undergraduate and graduate degrees from Southern Utah University and his MBA from Stephen M.
Ross School of Business.

Mark Andersen active positions

CompaniesPositionStart
FIBROBIOLOGICS, INC. Director of Finance/CFO 31/05/2022
All active positions of Mark Andersen

Former positions of Mark Andersen

CompaniesPositionEnd
Director of Finance/CFO 30/04/2022
Director of Finance/CFO 31/01/2016
ELI LILLY AND COMPANY Corporate Officer/Principal 31/07/2015
Comptroller/Controller/Auditor 31/12/1998
Comptroller/Controller/Auditor 31/12/1997
See the detail of Mark Andersen's experience

Training of Mark Andersen

Southern Utah University Graduate Degree
Stephen M. Ross School of Business Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark Andersen's experience

Connections

100 +

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
FIBROBIOLOGICS, INC.

Health Technology

ELI LILLY AND COMPANY

Health Technology

Private companies5

Commercial Services

Health Technology

Health Technology

Commercial Services

Commercial Services

See company connections